Project Grant 2212682
Award Date
2/1/23
Completion Date
1/31/24
Dollars Obligated
$256K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Briarcliff Manor, NY 10510, USA
Similar Awards
This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...
This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...
This Cooperative Agreement award of $996,606.00 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop stable prophylactic antibodies as long-term preventatives for infectious diseases such as influenza, malaria, tuberculosis, HIV, and the common cold. The project, awarded to Invvax, Inc., seeks to identify antibody mutations that significantly enhance stability, extending the lifespan of antibodies from weeks to years. This...
This Cooperative Agreement award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $1,000,000.00 in funding to Window Therapeutics, Inc. to develop a novel class of antibody-drug conjugates (ADCs) for treating metastatic cancer. The project aims to significantly increase the drug-to-antibody ratio of ADCs, allowing for the use of less toxic, yet more effective, cancer-killing drugs to be delivered directly to tumor cells. The goal is to...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,388 to Histone Therapeutics, a woman-owned small business, aims to epigenetically modify natural killer (NK) cells to enhance their ability to detect and kill cancer cells. The goal is to develop a broad-spectrum NK cell therapy that can be used in combination with current cancer treatments to improve effectiveness without increasing side effects. The project will assess...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
This Cooperative Agreement award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $1,250,000 in funding to Rattan Life Science Inc., a self-certified small disadvantaged business, for the development and validation of a novel platform technology to enable the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the...